FDA Designations and Development Progress - The US FDA granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS), highlighting the unmet medical need for patients with this rare disorder [1][2] - R289 also received Fast Track designation for the treatment of previously-treated transfusion-dependent lower-risk MDS patients [3] - The ongoing Phase 1b study of R289 is evaluating its safety, tolerability, pharmacokinetics, and preliminary activity in patients with lower-risk MDS who are relapsed or refractory to prior therapies [1] R289 Mechanism and Potential - R289 is a prodrug of R835, a dual inhibitor of IRAK1 and IRAK4, which blocks inflammatory cytokine production in response to TLR and IL-1R signaling [4] - Chronic stimulation of TLR and IL-1R pathways is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients [4] - Initial data from the Phase 1b study of R289 in lower-risk MDS patients is encouraging, supporting its potential as a new treatment option [2] Company Overview - Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer [5] - Founded in 1996, Rigel is based in South San Francisco, California, and is listed on the Nasdaq under the ticker RIGL [5]

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. To access the live webcast or archived recording, visit the Investor Relations sectio ...

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 46,131 stock options to eight non-executive employees vestin ...

Core Insights - Rigel Pharmaceuticals is considered undervalued due to its recent acquisition of a lung cancer targeted therapy and the growth of its IDH1 inhibitor [1] Company Analysis - The company has a focus on developing therapies for cancer, particularly lung cancer, which is a significant area of interest in the biotech sector [1] - The analyst has a strong background in biochemistry and experience in analyzing clinical trials, indicating a deep understanding of the scientific aspects of the company's products [1]

Core Viewpoint - Rigel Pharmaceuticals (RIGL) has seen a significant stock price increase of 53.5% over the past four weeks, closing at $22.74, with analysts suggesting a potential upside of 28.3% based on a mean price target of $29.17 [1] Group 1: Price Targets and Analyst Estimates - The mean price target is derived from six short-term estimates, with a standard deviation of $18.89, indicating variability among analysts [2] - The lowest estimate of $14 suggests a potential decline of 38.4%, while the highest estimate predicts a surge of 150.7% to $57 [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction and magnitude [7] Group 2: Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding RIGL's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 124.1%, with three estimates moving higher and no negative revisions [10] - RIGL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [11] Group 3: Caution on Price Targets - While price targets are often sought after by investors, their reliability as indicators of stock price direction is questionable [3][5] - Analysts may set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [8]

Company Overview - Rigel Pharmaceuticals, Inc. is a commercial stage biotechnology company focused on hematologic disorders and cancer [1][3] - The company was founded in 1996 and is based in South San Francisco, California [3] Upcoming Event - Dean Schorno, the chief financial officer of Rigel, will present a company overview at the Jefferies London Healthcare Conference on November 19, 2024, at 9:30 am GMT (4:30 am EST) [1] Investor Relations - Investors can access the live webcast or archived recording of the presentation through the Investor Relations section of Rigel's website [2]

Financial Data and Key Metrics Changes - In Q3 2024, Rigel Pharmaceuticals reported total net sales of $38.9 million, representing a 44% increase compared to Q3 2023 [9][52] - The company achieved a net income of $12.4 million in Q3 2024, compared to a net loss of $5.7 million in the same period in 2023 [58] - Cash, cash equivalents, and short-term investments increased to $61.1 million from $49.1 million [58] Business Line Data and Key Metrics Changes - TAVALISSE generated $26.3 million in net product sales in Q3 2024, an 8% increase from $24.5 million in Q3 2023 [52] - REZLIDHIA achieved net product sales of $5.5 million in Q3 2024, a 107% increase compared to $2.7 million in Q3 2023 [52] - GAVRETO, in its first full quarter, generated $7.1 million in net product sales [52] Market Data and Key Metrics Changes - Rigel expanded its product presence outside the US with a new agreement with Kissei to develop and commercialize REZLIDHIA in Japan, Korea, and Taiwan, including a $10 million upfront payment [10] - The company shipped 2,793 bottles of TAVALISSE, 444 bottles of REZLIDHIA, and 752 bottles of GAVRETO in Q3 2024 [50][51] Company Strategy and Development Direction - Rigel's corporate strategy focuses on expanding its commercial portfolio, advancing its pipeline through collaborations and internal development, and maintaining financial discipline [8][63] - The company aims to become self-sustaining and reinvest in its development pipeline, with plans to discuss development plans for R289 and olutasidenib in 2025 [63] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, highlighting strong commercial execution and the successful transition of GAVRETO into Rigel's portfolio [14][60] - The company is well-positioned to continue driving value as it heads into 2025, with expectations for continued revenue growth [15][63] Other Important Information - Rigel is advancing the development of R289, a dual IRAK1/4 inhibitor, in a Phase 1b study for lower-risk MDS, with initial safety and efficacy data to be presented at the ASH meeting [11][32] - The company is exploring opportunities to in-license or acquire late-stage hematology and oncology assets to further expand its portfolio [13][35] Q&A Session Summary Question: Can you provide more color on TAVALISSE regarding the balance between refills and new prescriptions? - Management indicated that the majority of TAVALISSE's business comes from carryover, with growth from both new patient starts and existing patients [67][68] Question: What is the status of GAVRETO orders from top centers? - Management noted that a handful of top centers have not placed orders yet, but overall business through specialty pharmacies is improving [70][71] Question: How much of a stocking benefit was there during the initial phase of GAVRETO's launch? - Management clarified that the majority of Q3 sales were true demand, with some initial stocking contributing to sales figures [75][76] Question: What is the bar for success for R289 in lower-risk MDS? - Management expressed excitement about the data and indicated that the study is unique in enrolling relapsed/refractory patients, which could differentiate it from existing treatments [82][84] Question: How does Rigel's R289 compare to other IRAK inhibitors? - Management highlighted that R289 is a dual IRAK1 and 4 inhibitor, which may provide more profound inhibition of inflammatory cytokines compared to other single-target inhibitors [90]

Financial Performance - Rigel's Q3 2024 net portfolio sales grew by $11.8 million, a 44% increase compared to Q3 2023[9] - TAVALISSE Q3 2024 net product sales were $26.3 million, an 8% increase compared to Q3 2023[14] - REZLIDHIA Q3 2024 net product sales were $5.5 million, a 107% increase compared to Q3 2023[16] - GAVRETO Q3 2024 net product sales were $7.1 million[21] - Contract revenues from collaborations were $16.4 million, including $13.0 million from Kissei and $3.3 million from Grifols[46] - Net income for Q3 2024 was $12.421 million, or $0.71 per share basic and $0.70 per share diluted, compared to a net loss of $5.692 million, or $(0.33) per share in Q3 2023[45] Product Sales and Distribution - 2,797 bottles of TAVALISSE were shipped to patients and clinics in Q3 2024, a 16% increase compared to Q3 2023[14] - 2,793 bottles of TAVALISSE were sold in Q3 2024, a 9% increase compared to Q3 2023[14] - 444 bottles of REZLIDHIA were shipped to patients in Q3 2024, a 101% increase compared to Q3 2023[16] - 429 bottles of REZLIDHIA were sold in Q3 2024, a 104% increase compared to Q3 2023[16] - 717 bottles of GAVRETO were shipped to patients and clinics in Q3 2024[21] - 752 bottles of GAVRETO were sold in Q3 2024[21] Strategic Initiatives - Rigel expanded its relationship with Kissei, granting exclusive rights for REZLIDHIA in Japan, the Republic of Korea, and Taiwan, receiving an upfront payment of $10.0 million with potential milestone payments of up to $152.5 million[17] - Rigel entered into a strategic alliance with MD Anderson Cancer Center to advance olutasidenib in AML and other cancers, with Rigel providing $15 million in time-based milestone payments and study material over the 5-year collaboration[31] - Rigel is collaborating with CONNECT to advance olutasidenib in glioma, providing funding up to $3 million and study material over the 4-year collaboration[32]

Company Performance - Rigel Pharmaceuticals reported quarterly earnings of $0.70 per share, significantly exceeding the Zacks Consensus Estimate of $0.01 per share, compared to a loss of $0.30 per share a year ago, representing an earnings surprise of 6,900% [1] - The company posted revenues of $55.31 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 35.92%, and showing an increase from $28.13 million in the same quarter last year [2] - Over the last four quarters, Rigel has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Market Performance - Rigel shares have increased approximately 4% since the beginning of the year, while the S&P 500 has gained 24.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $45.95 million, and for the current fiscal year, it is -$0.72 on revenues of $151.6 million [7] Industry Outlook - The Medical - Drugs industry, to which Rigel belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Rigel's stock performance [5][6]

[Q3 2024 Financial & Business Highlights](index=1&type=section&id=Q3%202024%20Financial%20%26%20Business%20Highlights) Rigel reported strong Q3 2024 results with **$55.3 million** total revenue, achieving profitability and advancing key commercial and clinical initiatives including a REZLIDHIA licensing deal Q3 2024 Revenue Breakdown | Metric | Amount | | :--- | :--- | | **Total Revenue** | **$55.3 million** | | TAVALISSE Net Product Sales | $26.3 million | | REZLIDHIA Net Product Sales | $5.5 million | | GAVRETO Net Product Sales | $7.1 million | - Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in Japan, the Republic of Korea, and Taiwan, receiving a **$10.0 million** upfront cash payment[1](index=1&type=chunk)[4](index=4&type=chunk) - Initial data from the Phase 1b study of R289, a dual IRAK1/4 inhibitor, in lower-risk myelodysplastic syndrome (LR-MDS) will be presented at the 66th ASH Annual Meeting[1](index=1&type=chunk) - The company's focus on financial discipline resulted in a positive third-quarter and year-to-date net income[2](index=2&type=chunk) [Business Update](index=1&type=section&id=Business%20Update) Rigel's business update highlights continued commercial momentum, successful GAVRETO integration, a key REZLIDHIA licensing deal, and clinical advancements for R289 and REZLIDHIA combination therapy [Commercial Update](index=1&type=section&id=Commercial%20Update) Rigel's commercial portfolio showed continued strength with record bottle shipments, successful GAVRETO patient transition, and a significant REZLIDHIA licensing agreement with Kissei Product Bottle Shipments | Product | Bottles Shipped to Patients/Clinics | Change in Distribution Channel | Total Bottles Shipped | | :--- | :--- | :--- | :--- | | **TAVALISSE** | 2,797 | (4) | 2,793 | | **REZLIDHIA** | 444 | (15) | 429 | | **GAVRETO** | 717 | 35 | 752 | - Entered an exclusive license agreement with Kissei for REZLIDHIA in Japan, South Korea, and Taiwan, receiving a **$10.0 million** upfront payment with potential for up to an additional **$152.5 million** in milestones[4](index=4&type=chunk) - Successfully transitioned existing GAVRETO patients to Rigel's product following its commercial launch in June 2024. A Dear Health Care Provider (DHCP) letter was issued in October regarding a new safety signal for GAVRETO[3](index=3&type=chunk)[5](index=5&type=chunk) [Clinical and Development Update](index=2&type=section&id=Clinical%20and%20Development%20Update) Rigel is advancing its clinical pipeline, highlighted by the ongoing Phase 1b study of R289 in LR-MDS with positive initial data and the initiation of a REZLIDHIA combination therapy trial - Initial data from the Phase 1b study of R289 in R/R LR-MDS showed the drug was well-tolerated. RBC-transfusion independence (RBC-TI) or hematologic improvement (HI-E) occurred in **36%** of patients receiving doses ≥500 mg QD[7](index=7&type=chunk) - Enrollment is underway in the fifth dose level (500mg / 250mg split dose) of the R289 Phase 1b study[6](index=6&type=chunk) - The first patient was enrolled in a Phase 1b/2 triplet therapy trial of REZLIDHIA in combination with decitabine and venetoclax, sponsored by MD Anderson Cancer Center[6](index=6&type=chunk) [Financial Performance Analysis](index=2&type=section&id=Financial%20Performance%20Analysis) Rigel demonstrated a significant financial turnaround, achieving profitability in Q3 and year-to-date 2024, driven by robust revenue growth from product sales and contract revenue, alongside improved cash position [Third Quarter 2024 Financial Results](index=2&type=section&id=Third%20Quarter%202024%20Financial%20Results) Rigel's Q3 2024 total revenues surged to **$55.3 million** from **$28.1 million** in Q3 2023, driven by product sales and contract revenues, resulting in a net income of **$12.4 million** or **$0.70** diluted EPS Q3 2024 Financial Summary | Financial Metric (in millions, except EPS) | Q3 2024 | Q3 2023 | YoY Change | | :--- | :--- | :--- | :--- | | **Total Revenues** | **$55.3** | **$28.1** | **+96.6%** | | TAVALISSE Net Sales | $26.3 | $24.5 | +7.3% | | REZLIDHIA Net Sales | $5.5 | $2.7 | +103.7% | | GAVRETO Net Sales | $7.1 | N/A | N/A | | Contract Revenue | $16.4 | $1.0 | +1540% | | Total Costs & Expenses | $41.3 | $32.6 | +26.7% | | **Net Income (Loss)** | **$12.4** | **($5.7)** | **Turned to Profit** | | **Diluted EPS** | **$0.70** | **($0.33)** | **Turned to Profit** | - The increase in costs and expenses was mainly due to higher cost of product sales, a sublicensing fee to Forma, increased royalties, amortization of intangible assets, and higher personnel and commercial-related expenses[8](index=8&type=chunk) [Year-to-Date (Nine Months) 2024 Financial Results](index=3&type=section&id=Year-to-Date%20(Nine%20Months)%202024%20Financial%20Results) For the nine months ended September 30, 2024, total revenues reached **$121.7 million**, a **50%** increase, resulting in a net income of **$3.1 million** or **$0.18** diluted EPS, reversing prior-year losses Year-to-Date Financial Summary | Financial Metric (in millions, except EPS) | YTD 2024 | YTD 2023 | YoY Change | | :--- | :--- | :--- | :--- | | **Total Revenues** | **$121.7** | **$81.1** | **+50.1%** | | TAVALISSE Net Sales | $73.8 | $68.1 | +8.4% | | REZLIDHIA Net Sales | $15.6 | $6.7 | +132.8% | | GAVRETO Net Sales | $9.0 | N/A | N/A | | Contract Revenue | $23.3 | $5.3 | +339.6% | | Total Costs & Expenses | $114.1 | $103.5 | +10.2% | | **Net Income (Loss)** | **$3.1** | **($25.8)** | **Turned to Profit** | | **Diluted EPS** | **$0.18** | **($1.49)** | **Turned to Profit** | - The increase in year-to-date costs was driven by higher cost of product sales and commercial expenses, partially offset by decreased R&D costs due to the timing of clinical trial activities[11](index=11&type=chunk) [Balance Sheet and Cash Position](index=3&type=section&id=Balance%20Sheet%20and%20Cash%20Position) As of September 30, 2024, Rigel's cash, cash equivalents, and short-term investments increased to **$61.1 million**, with total assets growing to **$139.4 million** Balance Sheet Summary | Balance Sheet Item (in millions) | Sep 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents & short-term investments | $61.1 | $56.9 | | Total Assets | $139.4 | $117.2 | | Stockholders' Deficit | ($14.6) | ($28.6) | [Company and Product Portfolio Overview](index=4&type=section&id=Company%20and%20Product%20Portfolio%20Overview) Rigel Pharmaceuticals is a biotechnology company focused on hematologic disorders and cancer, with a commercial portfolio including TAVALISSE, REZLIDHIA, and GAVRETO for various indications [Marketed Products](index=4&type=section&id=Marketed%20Products) Rigel markets three key products: TAVALISSE for chronic ITP, REZLIDHIA for relapsed or refractory AML with IDH1 mutation, and GAVRETO for metastatic RET fusion-positive NSCLC and thyroid cancer - **TAVALISSE (fostamatinib):** Indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment[20](index=20&type=chunk) - **REZLIDHIA (olutasidenib):** Indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation[21](index=21&type=chunk) - **GAVRETO (pralsetinib):** Indicated for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients (12+) with advanced or metastatic RET fusion-positive thyroid cancer[22](index=22&type=chunk) [Target Diseases](index=4&type=section&id=Target%20Diseases) Rigel's therapeutic focus addresses significant unmet needs in Immune Thrombocytopenia (ITP), Acute Myeloid Leukemia (AML), and Non-Small Cell Lung Cancer (NSCLC) - **Immune Thrombocytopenia (ITP):** An autoimmune disorder where the body attacks its own platelets, leading to excessive bruising and bleeding[16](index=16&type=chunk) - **Acute Myeloid Leukemia (AML):** A rapidly progressing cancer of the blood and bone marrow, primarily affecting adults. Relapsed or refractory AML presents a significant treatment challenge[17](index=17&type=chunk)[18](index=18&type=chunk) - **Non-Small Cell Lung Cancer (NSCLC):** The most common type of lung cancer, accounting for **80-85%** of all diagnoses. RET fusions are implicated in approximately **1-2%** of NSCLC cases[19](index=19&type=chunk)